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Abstract
Background: Lung protective mechanical ventilation (MV) is the corner stone of therapy for ARDS. However, its use
may be limited by respiratory acidosis.
This study explored feasibility of, effectiveness and safety of low flow extracorporeal CO2 removal (ECCO2R).
Methods: This was a prospective pilot study, using the Abylcap® (Bellco) ECCO2R, with crossover off-on-off design
(2-h blocks) under stable MV settings, and follow up till end of ECCO2R. Primary endpoint for effectiveness was a
20% reduction of PaCO2 after the first 2-h. Adverse events (AE) were recorded prospectively.
We included 10 ARDS patients on MV, with PaO2/FiO2 < 150 mmHg, tidal volume≤ 8 mL/kg with positive end-expiratory
pressure ≥ 5 cmH2O, FiO2 titrated to SaO2 88–95%, plateau pressure ≥ 28 cmH2O, and respiratory acidosis (pH <7.25).
Results: After 2-h of ECCO2R, 6 patients had a ≥ 20% decrease in PaCO2 (60%); PaCO2 decreased 28.4% (from 58.4 to 48.
7 mmHg, p = 0.005), and pH increased (1.59%, p = 0.005). ECCO2R was hemodynamically well tolerated. During the
whole period of ECCO2R, 6 patients had an AE (60%); bleeding occurred in 5 patients (50%) and circuit thrombosis in 3
patients (30%), these were judged not to be life threatening.
Conclusions: In ARDS patients, low flow ECCO2R significantly reduced PaCO2 after 2 h, Follow up during the entire
ECCO2R period revealed a high incidence of bleeding and circuit thrombosis.
Trial registration: https://clinicaltrials.gov identifier: NCT01911533, registered 23 July 2013.
Keywords: Acute respiratory distress syndrome, Lung protective mechanical ventilation, Extracorporeal carbon dioxide
removal, Plateau pressure, Driving pressure
Background
Acute Respiratory Distress Syndrome (ARDS) is a fre-
quently occurring disorder in critically ill patients, and is
associated with poor short-term and long-term out-
comes [1, 2]. Lung protective mechanical ventilation
(MV), i.e. use of a tidal volume (VT) of 6 mL/kg pre-
dicted body weight (PBW) and plateau pressure (PPLAT)
lower than 30 cmH2O has been shown to lead to im-
proved outcomes [3–5]. This is likely explained by de-
creasing overdistention and alveolar wall stress, and
consequently decreased local and systematic inflamma-
tory response [6]. Recent data suggest that reducing
driving pressure (the difference between PPLAT and posi-
tive end-expiratory pressure (PEEP) (PPLAT-PEEP)), using
MV with even lower VT, and limiting respiratory rate
may offer additional benefit [7–11].The use of lower VT
and lower respiratory rate may be limited by decreased
elimination of CO2 with resulting hypercapnia and re-
spiratory acidosis. This may in turn lead to increased
pulmonary shunt, elevated intracranial pressure, pul-
monary hypertension, decreased myocardial contractility,
decreased renal and splanchnic blood flow and the release
of endogenous catecholamines [12, 13]. Moderate permis-
sive hypercapnia is generally well tolerated when ventilat-
ing in a lung-protective manner. But the effect on survival
of hypercapnic acidosis compared to low-tidal volume re-
mains unclear [14]. In patients with normal kidney
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function, metabolic adaptation will compensate for re-
spiratory acidosis, but this process takes some days.
In 1977 Kolobow et al. evaluated the use of extracor-
poreal CO2 removal (ECCO2R) in an animal model [15];
subsequently, Gattinoni et al. first used ECCO2R in pa-
tients with acute respiratory failure in 1986 [16].
ECCO2R can be performed using a blood flow (Qb) ran-
ging from 300 to 1500 mL/min. Published experience
with ECCO2R in ARDS patients consists mainly of co-
hort studies [17–21]. Some authors reported the use of
ECCO2R in series with continuous renal replacement
therapy (CRRT), offering an additional method of cor-
recting acidosis. In these studies only patients who pre-
sented with acute kidney injury and ARDS were
included [17–19].
Using a previous generation of pumpless arterio-venous
ECCO2R, Bein et al. showed that this technique allowed
protective MV with VT of 3 mL/kg [22]. Fanelli et al. dem-
onstrated that low-flow ECCO2R can safely be applied to
facilitate ultra-protective MV with VT of 4 mL/kg [23].
Since these effects were evaluated over several days, also
metabolic adaption and improvement of gas exchange
may have contributed to the pH, and the exact contribu-
tion of ECCO2R on pH control versus mechanical ventila-
tion is uncertain.
The aim of our pilot study was to explore the short-
term (2-h) effects of low-flow ECCO2R in steady state
conditions in ARDS patients. In addition, we studied
feasibility and adverse events of this treatment with spe-
cial emphasis on bleeding and thrombosis.
Methods
Setting and patients
A prospective pilot study was conducted in the Intensive
Care Unit of Ghent University Hospital, between Decem-
ber 2013 and May 2015. The ICU comprises a 14 beds
medical, a 22 beds surgical and 10 beds cardiac surgical
ICU. A convenience sample of 10 patients was included.
Patients had to meet all of the following criteria for inclu-
sion: 1. acute onset of moderate or severe ARDS, with a
PaO2/FiO2 < 150 mmHg [24], 2. at least two hours of MV
applying a VT of 8 mL/kg PBW or less, with a positive
end-expiratory pressure (PEEP) of 5 cmH2O or more, and
FiO2 titrated to maintain an arterial oxygen saturation of
88–95% (PaO2 55–80 mmHg), 3. PPLAT of 28cmH2O or
higher, 4. respiratory acidosis with pH < 7.25, 5. informed
consent obtained from the patient or the proxy. Exclusion
criteria were: 1. age < 18 years, 2. pregnancy, 3. obesity
with a body mass index higher than 30 kg/m2, 4. contra-
indication for anticoagulation with unfractionated heparin,
5. Underlying chronic restrictive cause of respiratory acid-
osis, such as severe chest wall abnormalities.
Inhaled nitric oxide, muscle relaxants, and prone posi-
tioning were administered according to the discretion of
the attending physician. PBW was calculated based upon
patients’ length (measured with a measuring tape), for
male patients: 50 + 0.91 · (cm of height – 152.4) kg, and
for female patients: 45.5 + 0.91 · (cm of height – 152.4)
kg [3]. Sedation was monitored at 8-h intervals, using
the Richmond Agitation Sedation Score (RASS).
Study design
This paper discusses the results of a prospective single
center pilot study with a crossover design.
To assess the immediate effects of ECCO2R on gas ex-
change, we used a crossover design alternating periods
with (“on”) and without (“off”) ECCO2R. The first 2-h
study period without ECCO2R started as soon as the
venous access for ECCO2R was in place. Following this,
a first 2-h “on”-period was initiated with a Qb of
300 mL/min. The fraction of delivered oxygen via the
oxygenator was kept at 1.0 with a gas flow of 7 L/min
during “on”-periods. Hereafter followed the second 2-h
“off”-period by setting the gas flow through the ECCO2R
oxygenator at 0 L/min. Qb remained unchanged during
this second “off”-period. During these 3 study periods,
the settings for MV remained unchanged. After this sec-
ond “off”-period, a second “on”- period was started, the
gas flow was set again at 7 L/min and the Qb was in-
creased to 400–500 mL/min. This “on”-period lasted as
long as clinically indicated.
Extracorporeal CO2 removal
Veno-venous ECCO2R was performed with the Abylcap®
(Bellco®) device, mounted on a “Bellco” extracorporeal
therapy machine. The Lynda® with a theoretical maximal
Qb of 400 mL/min was used in the first 7 patients and
the Amplya™ with a theoretical maximal Qb of 500 mL/
min in the others.
A dedicated team of intensivists, dialysis nurses, ICU
nurses, and perfusionists managed the extracorporeal
therapy.
The Abylcap® device contains the Lilliput 2 (LivaNova)
oxygenator; this is a polymethylpentene hollow fiber oxy-
genator, phosphorylcholine coated, with a surface of
0.67m2 and a priming volume of 90 mL. The priming vol-
ume of the entire heparin-coated set without oxygenator
is 109 mL. Venous access was obtained preferentially via
the femoral vein with a 24 cm, 13.5 French double lumen
catheter (Niagara™, Bard). Blood was pumped through the
oxygenator via a non-occlusive roller pump.
Anticoagulation was performed with unfractionated
heparin (UFH). After an initial bolus dose of 10 IU UFH/
kg, heparin infusion was titrated to achieve an activated
clotting time (ACT) of 180–220 s. ACT was measured
every 30 to 60 min and once heparin titration was stable,
every 4 h. ACT was monitored with the Medtronic ACT
plus® system or the Hemochron ® signature elite.
Peperstraete et al. BMC Anesthesiology  (2017) 17:155 Page 2 of 9
Mechanical ventilation
During the first six hours of the study period, the treat-
ing physicians were advised not to change the MV set-
tings. This allowed evaluating the effects of ECCO2R
alone during this initial study period. From the start of
the second “on”-period, MV was left at the discretion
of the treating physician; with the only recommenda-
tion that of ventilating the patient as lung-protective as
possible. Practically, MV settings were aimed toward
PPLAT < 25cmH2O and VT < 6 mL/PBW. The “higher
FiO2 and lower PEEP” protocol of the ALVEOLI study
was proposed [25]. We recommended setting of re-
spiratory rate lower than 30/min. Inversed ratio was
not allowed.
Data management & analysis
During the first 6-h study period, MV parameters, arter-
ial blood gas analysis and ECCO2R parameters were col-
lected every two hours. Hereafter, data were recorded
per 8 h. In addition, all adverse events, with special em-
phasis on bleeding events, thrombosis, and transfusion
requirements were prospectively recorded.
The Murray score was calculated using the calculator
on the “Cesar-trial” website http://cesar.lshtm.ac.uk/
murrayscorecalculator.htm.
In order to have an objective judgment for bleeding,
this was scored according the Bleeding Academic Re-
search Consortium (BARC), and the Global Utilization of
Streptokinase and Tpa for Occluded arteries (GUSTO)
definitions for bleeding [26]. For a detailed description of
the BARC and GUSTO definitions, please find an add-
itional file as an online supplement (Additional file 1).
The primary endpoint was a reduction of 20% in arter-
ial carbon dioxide pressure (PaCO2) after the two hours
of ECCO2R therapy. Secondary endpoints were the
short-term effect of ECCO2R on pH, feasibility of per-
forming the technique, and bleeding and circuit throm-
bosis during ECCO2R treatment. In addition, we report
the ventilation parameters and blood gasses after 5-d of
ECCO2R.
A statistical package (SPSS Statistics version 22 (IBM®)
was used to perform statistical analysis. Since the small
number of patients included, data were considered not
normally distributed. Variables were reported as median
[inter quartile range] or number (proportion). Compari-
son of related variables was tested with the Wilcoxon
Signed Rank test. A p-value of 0.05 was considered
significant.
Results
The baseline characteristics of the included patients are
presented in Table 1. The median duration of ECCO2R
therapy was 6 days [5; 12]. Four patients were initiated
on CRRT during the study. CRRT was started at earliest
after 10 h of ECCO2R therapy, so after the initial “off-
on-off” evaluation. When CRRT was used, this was with
separate vascular access. The maximum Qb during the
second on-period of ECCO2R was 400 mL/min [399;
410]. At day 1 median heparin dosage was 19.5 IU/kg/h
[11.0; 25.4] with an ACT of 211 s [186; 225].
ICU survival was 70%, hospital survival was 60%, and
survival at day 28, and 90 was respectively 60% and 60%.
In 4 patients, ECCO2R was the upper limit of life sup-
port, as after team discussions, these patients were not
deemed to be candidates for extracorporeal membrane
oxygenation (ECMO) therapy. Three patients died in the
ICU because of limitations in therapy unrelated to
ECCO2R.
Short term effects of ECCO2R
The protocol required settings of the MV to be un-
altered during the 6-h crossover, in order to be able to
Table 1 Baseline characteristics
Baseline characteristics N (%) or median [IQR]
Number of patients included 10 (100%)
Age (y) 50.5 [34.8; 63.3]
Gender Male 6 (60%)/female 4 (40%)
SAPS 3 score 72.5 [61.0; 79.3]
Characteristics at inclusion
Length of ICU stay before
inclusion (h)
26 [20.5; 67.5]
Days with ARDS criteria on CT
scan or chest radiography on
the day of inclusion
2 [1; 3.25]
SAPS 3 score 69.5 [57.75; 79.25]
Vasopressor use 10 (100%)
RRT use 0
PaCO2 (mmHg) 68.3 [57.7; 86.2]
pH 7.21 [7.11; 7.23]
PaO2/FiO2 (mmHg) 83 [67.6; 121.1]
Murray score 3.5 [3.2; 3.5]
Moderate ARDS (PaO2/FiO2:
100–200 mmHg)
4 (40%)
Severe ARDS (PaO2/FiO2
< 100 mmHg)
6 (60%)
Nitric Oxide inhalation 6 (60%)
Neuromuscular blockers 10 (100%)
Prone ventilation 2 (20%)
PPLAT (cmH2O) 31.5 [28.8; 35.5]
Driving pressure
(PPLAT –PEEP) (cmH2O)
19.0 [17.5; 24.0]
VT/PBW (mL/kg) 6.9 [6.31; 7.48]
y Years, SAPS 3 simplified acute physiology score 3, RRT Renal replacement
therapy, PaCO2 Partial pressure of arterial carbon dioxide, PaO2/FiO2 the ration
of partial pressure of arterial oxygen and fraction of inspired oxygen, PPLAT
Plateau pressure, VT tidal volume, PBW Predicted body weight
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study the short-term effects of ECCO2R in steady state
conditions. In one patient the treating physician modi-
fied MV settings during the first off period, with result-
ing decrease of PaCO2 (132 to 58 mmHg). In order to
secure the detection of the effect of ECCO2R, ventilation
conditions remained unchanged for the next four hours.
PCO2 values of this patient have been withdrawn from
analysis of the first “off” -period (fig. 1a). Median PaCO2
remained stable during the first 2-h “off”-period (delta
change −8.6% [−11.4; 3.0], p = 0.441), decreased during
the “on”-period (−28.4% [−12.2; −34.3], p = 0.005), and
subsequently increased during the second “off”-period
(32.6% [18.5; 36.8], p = 0.005). During the 2-h on period
6 patients (60%) had a decrease in PaCO2 of 20% or
greater (fig. 1b).
Median pH remained stable during the first 2-h “off”-
period (delta change 0.28% [−0.07; 0.76], p = 0.078) (fig-
ure1d), increased during the first “on”-period (1.59%
[0.49; 2.02], p = 0.005) (fig. 1e), and decreased again dur-
ing the second “off”-period (−1.28% [−1.50; −0.77], p =
0.005) (fig. 1f ).
Feasibility and adverse events
Insertion of the double lumen catheter was troublesome
in 2 patients (20%). One patient (10%) had transfusion
of 1 unit of RBCs after insertion of the catheter. One pa-
tient (10%) had premature cessation after 6-h of
ECCO2R for presumed hemorrhagic pericardial effusion.
This finding was not confirmed after cessation of
therapy.
During ECCO2R, bleeding was observed in 5 patients
(Table 2). Patient 3 had a nosebleed and was bleeding at
the insertion points of the ECCO2R catheter and the
central venous catheter. Patient 4 was bleeding at the in-
sertion point of the ECCO2R catheter, had a pharyngeal
bleeding and hematuria. Patient 5 was bleeding during
insertion of the catheter. Patient 7 had minor bleeding
during tracheal and pharyngeal aspirations. Patient 9
was bleeding at the insertion point of the ECCO2R cath-
eter. According to the GUSTO criteria and BARC defini-
tions, bleeding was scored in 4 patients (40%) as
moderate or 3a, and in 1 patient (10%) as mild or 2 [26].
Five patients (50%) received transfusion of red blood
Fig. 1 Evolution of PaCO2 during the 6-h off-on-off period. a: Evolution of PaCO2 during the first 2-h off period. b: Evolution of PaCO2 during the
first 2-h on period. c: Evolution of PaCO2 during the second 2-h off period. d: Evolution of pH during the first 2-h off period. e: Evolution of pH
during the first 2-h on period. f: Evolution of pH during the second 2-h off period. This figure was created with Excel (Office)
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cells. In none of the patients, bleeding resulted in
hemodynamic instability.
In 3 patients (30%), clots were observed in the circuit.
In 2 patients (20%), clotting of the circuit occurred after
temporary stop of the heparin infusion because of in-
creased ACT results.
We observed transient and short-lasting alkalemia (de-
fined as pH > 7.45) in 8 patients (80%).
Evolution of ventilation and blood gasses after 5-d
ECCO2R
Plateau pressure, PPLAT-PEEP and VT/PBW were signifi-
cantly reduced after 5 days of therapy (Table 3). This
was accompanied with a steady increase of bicarbonate
and pH. Median pH at the moment of decision of wean-
ing from ECCO2R was 7.42 [7.39; 7.44].
A significant increase in PaO2/FiO2 was noted, indicat-
ing amelioration of ARDS.
Discussion
In this prospective crossover pilot study in patients with
moderate or severe ARDS, we found that with stable
MV settings, low flow ECCO2R resulted in a rapid de-
crease of PaCO2 with almost one-third. During the
whole treatment period, we observed a high incidence of
bleeding and thrombosis.
In our study, we evaluated the short-term effects of
ECCO2R in steady state MV conditions, using study pe-
riods of 2-h. It is therefore reasonable to presume that
changes in PaCO2 can be attributed to the effects of
ECCO2R only, and were not obscured by an improve-
ment of respiratory function, metabolic compensation,
or change in settings of the mechanical ventilator. This
is an important aspect that was not studied before. Sev-
eral other studies have reported the beneficial effects of
ECCO2R on PaCO2 in ARDS patients. However these
differed from our study in study design, the non-
reporting of short-term effects, combined use with
CRRT, and the use of other devices such as pumpless
arterio-venous devices [17, 19, 21–23, 27]. An important
advantage of this low flow veno-venous ECCO2R treatment
is that Qb up to 500 mL/min can be achieved by using a
catheter that is also used for CRRT, making it a less inva-
sive technique compared with others that are using an ar-
terial catheter or large bore wire-reinforced ECMO
cannulas [22, 23, 27–30]. However, it should be noted that
despite our use of relatively small-bore catheters of 13.5F,
catheter insertion was difficult in two patients.
We observed some variability in response to ECCO2R.
A possible explanation for this may be a difference in
volume of distribution of CO2. Two main components
that determine CO2 removal are Qb and sweep gas flow.
Here we used a Qb of 300 mL/min during the first “on”-
period of our study, in which we demonstrated an almost
30% decrease of CO2. In the second “on”-period, a median
Qb of 400 mL/min allowed adequate removal of CO2.
Our findings are in contrast to others who have reported
higher Qb. For instance, Karagiannidis et al. suggested in
their study in pigs a QB of 750 to 1000 mL/min for effi-
cient CO2 removal [31], and Bein et al. used in vivo a Qb
of 2.2 L/min for the A-V iLA device [27, 32]. An explan-
ation for the efficacious CO2 removal despite low Qb in
our study may be the deep sedation used in our patients,
limiting CO2 production. Another determinant for CO2
removal is sweep gas flow. In this study the sweep gas flow
was kept at 7 L/min, with a FiO2 of 1.0, since we found in
a previous study that CO2 removal rate only marginally
improved above gas flows of 6 L/min [33].
After 5 days of ECCO2R we observed a marked de-
crease in PPLAT, PPLAT-PEEP and VT. This resulted in a
more lung protective strategy of MV with ventilation
settings of VT, PPLAT and driving pressure below the
Table 2 Bleeding, clotting in circuit and transfusion needs
Patient no Clotting in circuit Bleeding Transfusion Cumulative Units of PC during ECCO2R GUSTO bleeding criteria BARC type
1 0 0
2 0 0
3 Y Y 4 moderate 3a
4 Y Y Y 4 moderate 3a
5 Y Y Y 3 moderate 3a
6 1 0
7 Y 0 mild 2
8 1 0
9 Y Y 3 moderate 3a
10 Y Y 2 0
total 3/10 5/10 5/10 1.5 [0; 3.25]
“Y” yes, an empty box means no, PC Packed Cells, GUSTO Global Utilization of Streptokinase and Tpa for Occluded arteries definition of bleeding, BARC Bleeding
Academic Research Consortium definition for bleeding
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currently recommended [7–10]. Decreased VT, PPLAT
and PPLAT-PEEP without an increase in PaCO2 may offer
benefits for ARDS patients, since it may lead to a further
decrease of inflammatory mediators in broncho-alveolar
fluid and systemic circulation, which in turn may contrib-
ute to less lung damage and improved outcomes [17, 23].
Since pH was still 7.43 at day 5, it might have been feasible
to achieve even more pronounced decreases of mechan-
ical ventilation settings.
Adequate anticoagulation remains challenging in the
management of ECCO2R-patients. In our study, 30% of
all patients experienced some form of circuit thrombosis.
This was accompanied with a temporal increase in
PaCO2 and consequent change of the ventilator to less
lung protective settings. We also observed bleeding and
need for transfusion of red blood cells in 50% of pa-
tients. Others have also reported bleeding and blood loss
as an important complication of ECCO2R [22, 27, 34].
This complication seems to occur more frequently in
ECCO2R compared to CRRT (16%), a well-established
extracorporeal therapy for AKI [35]. We can only specu-
late on the etiology of bleeding in these patients. Poten-
tial causes could be the poor correlation of both ACT
and aPTT with the heparin concentration [36, 37], and
the activation of platelets and induction of other coagu-
lation abnormalities by unfractionated heparin and/or
the ECCO2R circuit [38].The use of visco-elastic moni-
toring such as TEG, RoTEM or Sonoclot, preferable in
combination with a platelet function test may allow bet-
ter monitoring of coagulation in these patients.
Strengths of our study are the prospective crossover
design with detailed short-term evaluation of the effects
of ECCO2R. This allowed us to evaluate the effects of
ECCO2R with the patient serving as its own control. In
addition, we reported the adverse events, more in par-
ticular bleeding, meticulously and in a structured way
according to the validated GUSTO and BARC scales. As
until now, no RCT’s have proven advantage over permis-
sive hypercapnia, it is important to quote the principle
‘primum non nocere’ to guide clinicians considering
ECCO2R. Finally, this study evaluated ECCO2R in mod-
erate (n = 4) and severe ARDS patients (n = 6), and as
such reflects the recommended cohort of ARDS patients
that may benefit of ECCO2R [24]. We want to discuss
the following limitations of this pilot study. We report
data on a small number of patients in a single center set-
ting. Second, we may have underestimated the short-
term effects of ECCO2R during the first six hours of our
study period as we only used a Qb of 300 mL/min.
Third, reduction of VT, PPLAT and driving pressure were
the main goals of management of MV in this study. Re-
cently, the large epidemiologic LUNG SAFE study
showed that a lower respiratory rate is also associated
with better patient outcomes [39]. These results were
not available at time of the initiation of the study, and
decreasing respiratory rate was therefore not set as a
goal for MV here. Finally, we can only speculate on the
efficacy of ECCO2R using low Qb in patients who are
more awake.
Conclusions
We showed the feasibility of CO2 removal with a low
flow ECCO2R device in patients with moderate and se-
vere ARDS. Crossover design allowed us to evaluate the
short-term effects of ECCO2R in steady state conditions,
with the patient serving as his own control, and demon-
strated an almost one-third decrease of PaCO2 within a
2-h study period. However, ECCO2R treatment was as-
sociated with bleeding in half of the patients and circuit
thrombosis in one third. These complications should be
explored in greater detail and may be a major barrier for
larger studies on efficacy of ECCO2R.
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